Gossamer Bio Announces Failed Phase 3 Trial Results, Leading to Sharp Stock Decline
Gossamer Bio, Inc. (GOSAM) announced the failure of its Phase 3 PROSERA study, which did not meet the primary endpoint of improved six-minute walk distance. The stock price dropped over 80% following the announcement. A class action lawsuit has been filed against the company for alleged misleading statements regarding the study design.
Tickers: $GOSS
Topics: class action legal proceedings Phase 3 trial failure securities fraud stock price drop